Verisante Technology said this week that it has received the first orders for its Raman spectroscopy-based Aura skin cancer detection system and plans an initial production run of 10 devices to be placed in Canada and Europe.
The company will begin shipping the devices this month to its Canadian distributor Clarion and Laserwelt, its distributor for Germany, Austria, and Liechtenstein.
Sales of the device were originally slated to launch in the middle of 2012. This launch was delayed, however, by improvements to the device that necessitated additional beta testing as well as recently added electrical safety testing rules in Europe, Verisante CEO Thomas Braun told ProteoMonitor in a November interview (PM 11/30/2012).
The Aura uses Raman spectroscopy to measure the levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions to distinguish between benign and malignant lesions. By comparing the patterns of spectra generated by the device, clinicians can differentiate between the two.
The sales clear the way for Verisante to move toward US Food and Drug Administration approval for the device, which the company has delayed pursuing pending its commercial launch.